Skip to main content
Premium Trial:

Request an Annual Quote

Atlas Genetics Completes $27.3M Series B Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Infectious disease test development firm Atlas Genetics announced this week the completion of a Series B financing round that raised £16.9 million ($27.3 million).

The funds, to be drawn down over three years, will be used to accelerate the launch of Atlas' Velox point-of-care products for chlamydia and gonorrhea, as well as for the development of other tests and to expand the immunoassay capability of the Velox system, the Bristol, UK-based company said.

Velox is a molecular diagnostic platform that runs assays for the detection of DNA and RNA using electrochemistry. According to Atlas' website, its single-use test cartridges contain all the reagents that are needed to extract DNA, amplify a specific sequence, and detect the target.

The technology uses target-specific probes labeled with an electronic ferrocene tag. After the pathogen DNA is copied, the probe is added, which then binds with the pathogen DNA. This, in combination with a specific enzyme, makes detection of an electronic signal possible.

Leading the financing round was new investor Novartis Venture Funds and existing investor Consort Medical. Other new investors included Life Science Partners, BB Biotech Ventures, and Johnson & Johnson Development.

In February, Atlas raised £1.5 million when Consort Medical took a 20 percent stake in the company. Spun out of Bath University, it raised about $4.1 million in 2008.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.